RUA Life Sciences PLC Exercise of Warrants, Issue of Equity & TVR (8311C)
October 21 2020 - 11:21AM
UK Regulatory
TIDMRUA
RNS Number : 8311C
RUA Life Sciences PLC
21 October 2020
RUA Life Sciences plc
("RUA", the "Company" or the "Group")
Exercise of Warrants
Issue of Equity
and
Total Voting Rights
RUA Life Sciences plc (AIM: RUA.L), the holding company of a
group of medical device businesses focused on the exploitation of
the world's leading long-term implantable biostable polymer
(Elast-Eon(TM)), announces that it has received notification from
Shore Capital for the exercise of warrants held by Stockdale
Securities Limited over 166,667 ordinary shares of 5 pence each in
the Company ("Ordinary Shares") at an exercise price of 30 pence
per share providing the Company with proceeds of GBP50,000.10.
Application has therefore been made for 166,667 new Ordinary
Shares to be admitted to trading on AIM. Admission is expected to
occur at 8.00 a.m. on 23 October 2020.
Following Admission, the Company will have 16,353,275 Ordinary
Shares in issue and admitted to trading on AIM. This figure may be
used by Shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the Financial Conduct Authority's Disclosure Guidance and
Transparency Rules.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information contact:
RUA Life Sciences
Bill Brown, Chairman Tel: +44 (0) 77 3071 8296
David Richmond, CEO Tel: +44 (0) 78 99996400
Shore Capital
Tom Griffiths/David Coaten Tel: +44 (0)20 7408 4080
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA
Life Sciences Plc (formerly known as AorTech International Plc)
acquired RUA Medical Devices Limited to create a fully formed
medical device business. RUA Life Sciences is the holding company
of the Group's four trading businesses, each exploiting the Group's
patented polymer technology.
Our vision is to improve the lives of millions of patients by
improving and enabling medical devices with Elast-Eon(TM) , the
world's leading long-term implantable polyurethane.
Whether it is licensing Elast-Eon(TM) , manufacturing a device
or component or developing next generation medical devices, a RUA
Life Sciences business is pursuing our vision.
Elast-Eon(TM)'s biostability is comparable to silicone while
exhibiting excellent mechanical, blood contacting and flex-fatigue
properties. These polymers can be processed using conventional
thermoplastic extrusion and moulding techniques. With over 7
million implants and over 14 years of successful clinical use,
RUA's polymers are proven in long-term life enabling
applications.
The Group's four business units are:
RUA Medical : End-to-end contract developer and manufacturer
of medical devices and implantable fabric specialist.
RUA Biomaterials Licensor of Elast-Eon(TM) polymers to the medical
: device industry.
RUA Vascular: Development of large bore polymer sealed grafts
and soft tissue patches.
RUA Structural Development of tri leaflet polymeric heart valves.
Heart :
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEMBBATMTTTBMM
(END) Dow Jones Newswires
October 21, 2020 11:21 ET (15:21 GMT)
Aortech (LSE:AOR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aortech (LSE:AOR)
Historical Stock Chart
From Jul 2023 to Jul 2024